RxDoctor Payments DataLook up a doctor →

Alan Haratz, MD

Nephrology · Eatontown, NJNPI 1336155688

Payments from drug & device makers

$7,834in general payments, 2019–2025

Across 450 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Bayer$948
  • Amgen$853
  • Aurinia Pharma U.S., Inc.$844
  • OPKO Pharmaceuticals, LLC$574
  • Vifor Pharma, Inc.$386
  • plus $3K from 32 others

What the payments were for

  • Consulting fees$1141%
  • Food & beverage$7,50096%
  • Education$2203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,834 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$129,465
Medicare patients
172
Services billed
19,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayaldeeCalcifediol74$89,936
VeltassaPatiromer Calcium Sorbitex61$89,896
OzempicSemaglutide48$46,280
FarxigaDapagliflozin Propanediol56$39,763
RybelsusSemaglutide28$36,825
EliquisApixaban49$32,525
JardianceEmpagliflozin25$26,260
KerendiaFinerenone25$20,578
Cinacalcet Hcl19$17,764
EntrestoSacubitril/Valsartan17$11,458
XareltoRivaroxaban11$10,268
Potassium Citrate ErPotassium Citrate29$7,235
Tresiba Flextouch U-200Insulin Degludec11$6,033
Rosuvastatin Calcium362$5,539
Sevelamer Carbonate12$4,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
OPKO Pharmaceuticals, LLCRayaldee$574$89,93674 claims
Novo NordiskOzempic, Rybelsus$99$83,10476 claims
AstraZenecaFarxiga$1,114$39,76356 claims
Boehringer IngelheimJardiance$228$26,26025 claims
BayerKerendia$948$20,57825 claims
NovartisEntresto$73$11,45817 claims
ANI Pharmaceuticals, Inc.Valsartan$32$1,02534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →